• Publications
  • Influence
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
BACKGROUND PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria, published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for PSP, haveExpand
  • 435
  • 40
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum.
Many drugs of abuse exert their addictive effects by increasing extracellular dopamine in the nucleus accumbens, where they likely alter the plasticity of corticostriatal glutamatergic transmission.Expand
  • 538
  • 39
Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus
Endocannabinoids form a novel class of intercellular messengers, the functions of which include retrograde signaling in the brain and mediation or modulation of several types of synaptic plasticity.Expand
  • 296
  • 26
Parsing Molecular and Behavioral Effects of Cocaine in Mitogen- and Stress-Activated Protein Kinase-1-Deficient Mice
Although the induction of persistent behavioral alterations by drugs of abuse requires the regulation of gene transcription, the precise intracellular signaling pathways that are involved remainExpand
  • 259
  • 20
Role of the ERK pathway in psychostimulant-induced locomotor sensitization
BackgroundRepeated exposure to psychostimulants results in a progressive and long-lasting facilitation of the locomotor response that is thought to have implications for addiction. PsychostimulantsExpand
  • 142
  • 16
Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease.
Pathogenic variants in the glucocerebrosidase gene (GBA) encoding the enzyme deficient in Gaucher's disease (GD) are associated with Parkinson's disease (PD). To investigate the sequence variants,Expand
  • 178
  • 13
Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.
Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous. The genetic causes of approximately 50% of autosomal-recessive early-onset forms of Parkinson disease (PD)Expand
  • 145
  • 9
Targeting chelatable iron as a therapeutic modality in Parkinson's disease.
AIMS The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a chelation strategy aimed at reducing oxidative damage associated with regional iron deposition without affectingExpand
  • 113
  • 7
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
We hypothesized that specific mutations in the β‐glucocerebrosidase gene (GBA) causing neuropathic Gaucher's disease (GD) in homozygotes lead to aggressive cognitive decline in heterozygousExpand
  • 99
  • 6
Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.
Patients with Parkinson's disease (PD) may experience impulse control disorders (ICDs) when on dopamine agonist therapy for their motor symptoms. In the last few years, a rapid growth of interest forExpand
  • 63
  • 5